Mylan Loses Bid To Dismiss MS Drug Patent Suit
U.S. District Judge Barbara S. Jones rejected Mylan's argument that the claims in Teva's Copaxone patents regarding the chemical composition of the drug and the process for making it were not explicitly defined, invalidating the patent.
Judge Jones settled the matter by deciding on claim constructions for certain terms and phrases in the...
Already a subscriber? Click here to login